Kelowna residents battling prostate cancer will have new treatment options and improved diagnostics as the province expands ...

The pivotal AMPLIFY trial aims to support FDA approval of ⁶⁴Cu-SAR-bisPSMA as a best-in-class imaging tool in prostate cancer ...

The aim of this trial is to investigate the ability of 64 Cu-SAR-bisPSMA PET/computed tomography (CT) to detect recurrence of prostate cancer, with evaluation across 2 imaging timepoints, Day 1 (day ...